Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: A randomized controlled trial

Kubomura,Daiki; Yamada,Masanori; Masui,Ayano

doi:10.3892/br.2016.701

Tuna extract reduces serum uric acid in gout-free subjects with insignificantly high serum uric acid: A randomized controlled trial

Authors:
- Daiki Kubomura
- Masanori Yamada
- Ayano Masui
View Affiliations

Affiliations: Yaizu Suisankagaku Industry Co., Ltd., Shizuoka 425‑8570, Japan
Published online on: June 9, 2016 https://doi.org/10.3892/br.2016.701
Pages: 254-258

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long-term reduction of serum urate levels is vital in the treatment of gout. However, it is difficult to convince gout‑free individuals of the necessity of treatment as few appropriate over‑the‑counter remedies and dietary supplements are available. Therefore, the present study aimed to investigate the antihyperuricemic efficacy and safety of a tuna extract containing the imidazole compounds to evaluate its potential as a functional food ingredient. A randomized, 4‑week, double‑blind, placebo‑controlled study was conducted. A total of 48 male gout‑free subjects with insignificantly high serum uric acid were randomly assigned to low‑ and high‑dose tuna extract groups or a placebo group. The efficacy of the extract was assessed by measuring serum uric acid levels. Furthermore, a safety assessment was performed by physical parameters, hematology, blood biochemistry and urinalysis. The results indicated that the uric acid level was decreased at week 4 during the intervention in the tuna extract groups (low and high dose, ‑0.23 and ‑0.34 mg/dl, respectively) compared to the placebo group (‑0.07 mg/dl). At week 4 after the intervention, a significant reduction in uric acid levels (‑0.41 mg/dl; P<0.05) was observed in the high‑dose tuna extract group compared with the placebo group (+0.11 mg/dl). No dose‑related adverse events were observed during and following the intervention. Therefore, the present results suggest that oral administration of tuna extract containing the imidazole compounds has hypouricemic activity with no undesirable side effects.

View Figures

View References

1	Choi HK and Ford ES: Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 120:442–447. 2007. View Article : Google Scholar : PubMed/NCBI
2	Wortmann RL: Gout and hyperuricemia. Curr Opin Rheumatol. 14:281–286. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ishizaka N, Ishizaka Y, Toda E, Nagai R and Yamakado M: Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 25:1038–1044. 2005. View Article : Google Scholar : PubMed/NCBI
4	Shoji A, Yamanaka H and Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 51:321–325. 2004. View Article : Google Scholar : PubMed/NCBI
5	Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 333:1600–1607. 1995. View Article : Google Scholar : PubMed/NCBI
6	Hande KR, Noone RM and Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 76:47–56. 1984. View Article : Google Scholar : PubMed/NCBI
7	Yamanaka H, Ueda T and Ohno I: Guideline for the management of hyperuricemia and gout (2nd). Medical Review Co., Ltd. Tokyo: 2010.
8	Kohen R, Yamamoto Y, Cundy KC and Ames BN: Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA. 85:3175–3179. 1988. View Article : Google Scholar : PubMed/NCBI
9	Abe H: Role of histidine-related compounds as intracellular proton buffering constituents in vertebrate muscle. Biochemistry (Mosc). 65:757–765. 2000.PubMed/NCBI
10	Boldyrev A, Bulygina E, Leinsoo T, Petrushanko I, Tsubone S and Abe H: Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. Comp Biochem Physiol B Biochem Mol Biol. 137:81–88. 2004. View Article : Google Scholar : PubMed/NCBI
11	Severin SE, Skolysheva LK, Shur SA and Vulfson PL: The pH-dependent conformational transition in glycogen phosphorylase b. The effect of carnosine and anserine on its activity. Biochem Int. 20:227–238. 1990.PubMed/NCBI
12	Ikeda T, Kimura K, Hama T and Tamaki N: Activation of rabbit muscle fructose 1,6-bisphosphatase by histidine and carnosine. J Biochem. 87:179–185. 1980.PubMed/NCBI
13	Chang WTH: Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide. US Patent 7498301. Filed December 22, 2006; issued March 3. 2009.
14	Abe H and Ohmama S: Effect of starvation and sea-water acclimation on the concentration of free l-histidine and related dipeptides in the muscle of eel, rainbow trout and Japanese dace. Comp Biochem Physiol Part B Comp Biochem. 88:507–511. 1987. View Article : Google Scholar
15	Williams DA: A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics. 27:103–117. 1971. View Article : Google Scholar : PubMed/NCBI
16	Noguchi Y, Shimizu J, Mano H, Matahira Y and Wada M: Effect of anserine administration on purine metabolism. Proceedings of 60th Annual Meeting of Japan Society of Nutrition and Food Science (Tokyo). 2682006.
17	Curto R, Voit EO and Cascante M: Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man. Biochem J. 329(Pt 3): 477–487. 1998. View Article : Google Scholar : PubMed/NCBI
18	Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 417:447–452. 2002.PubMed/NCBI
19	Kubomura D, Matahira Y, Masui A and Matsuda H: Intestinal absorption and blood clearance of L-histidine-related compounds after ingestion of anserine in humans and comparison to anserine-containing diets. J Agric Food Chem. 57:1781–1785. 2009. View Article : Google Scholar : PubMed/NCBI
20	Abe H, Okuma E, Sekine H, Maeda A and Yoshiue S: Human urinary excretion of L-histidine-related compounds after ingestion of several meats and fish muscle. Int J Biochem. 25:1245–1249. 1993. View Article : Google Scholar : PubMed/NCBI
21	Kessler T and Hesse A: Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects. Br J Nutr. 84:865–871. 2000.PubMed/NCBI
22	Baguet A, Reyngoudt H, Pottier A, Everaert I, Callens S, Achten E and Derave W: Carnosine loading and washout in human skeletal muscles. J Appl Physiol 1985. 106:837–842. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sato M, Karasawa N, Shimizu M, Morimatsu F and Yamada R: Safety evaluation of chicken breast extract containing carnosine and anserine. Food Chem Toxicol. 46:480–489. 2008. View Article : Google Scholar : PubMed/NCBI
24	Aoyagi S, Sugino T, Kajimoto Y and Nishitani M: Safety of excess administration of CBEX-Dr-containing drink on healthy people. Jpn Pharmacol Ther. 36:199–212. 2008.
25	Tanida M, Shen J, Kubomura D and Nagai K: Effects of anserine on the renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. Physiol Res. 59:177–185. 2010.PubMed/NCBI
26	Kubomura D, Matahira Y, Nagai K and Niijima A: Effect of anserine ingestion on hyperglycemia and the autonomic nerves in rats and humans. Nutr Neurosci. 13:183–188. 2010. View Article : Google Scholar : PubMed/NCBI